Beta–blockers are recommended for treatment of all patients with stabile heart failure from ischemic or non-ischemic etiology and reduced left ventricular ejection fraction in NYHA Class II to IV, as a standard therapy, including ACE-inhibitors and diuretics. The gene discussed is ACE; the disease is heart failure.